Testing Ondexxya for emergency reversal of blood thinners
Part of Blood & lymphatic, Injuries & trauma clinical trials.
This study looks at Ondexxya, a medicine used to reverse the effect of certain blood thinners during a dangerous bleeding emergency. It may help doctors better understand how to manage life-threatening bleeding caused by apixaban, rivaroxaban, or edoxaban.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been given Ondexxya to reverse a blood thinner called an FXa inhibitor
- The blood thinner you took was apixaban, rivaroxaban, or edoxaban
- The medicine reversal was used at the start of life-threatening bleeding
- Or it was used for bleeding that could not be stopped (an “unarrestable” bleeding episode)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clot-busting drug (thrombolysis) for people who had a stroke while on a Factor Xa inhibitor blood thinner. It aims to see if the drug can still safely break up the clot and reduce disability.
This Phase 3 study tests TAK-330, a reversal (blocking) medicine, to reduce bleeding risk during urgent surgery for adults taking Factor Xa inhibitors like rivaroxaban, apixaban, or edoxaban. It’s for situations where surgery can’t wait and doctors need a fast way to restore normal clotting.
This trial tests a drug called VMX-C001 to quickly reverse the effects of certain blood thinners (Factor Xa inhibitors) in people who need urgent surgery with a high risk of bleeding. It compares VMX-C001 to standard care to see which is more effective at helping blood clot normally.
This study looks at how the body processes a certain type of blood thinner (Xa factor inhibitors) to help doctors find the right dose for each person. If you have a blood clot in your lungs and are on long-term treatment, this trial might help improve your care.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This study tests if a medicine called tranexamic acid can safely reduce heavy bleeding during periods for people who are taking blood thinners for a recent blood clot. It is a pilot study to see if a larger trial is possible.
Hear when a new Life Threatening Bleeding trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.